Challenging issues in the management of extranodal lymphomas

Extranodal Lymphomas: Pathology and Management

Volumn , Issue , 2008, Pages 3-8

  Zucca, Emanuele ^a   Cavalli, Franco ^a  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650668162     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (42)

1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classifica - tion of Tumours, 3rd edn. Lyon: IARC Press, 2001:1-351.
3. Zucca E, Roggero E, Bertoni F, Cavalli F. Primary extranodal non-Hodgkin’s lymphomas. Part 1:gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol 1997; 8: 727-37.
4. Zucca E, Roggero E, Bertoni F, Conconi A, Cavalli F. Primary extranodal non-Hodgkin’s lymphomas. Part 2: Head and neck, central nervous system and other less common sites. Ann Oncol 1999; 10: 1023-33.
5. Dawson IM, Cornes JS, Morson BC. Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. Br J Surg 1961; 49: 80-9.
6. Lewin KJ, Ranchod M, Dorfman RF. Lymphomas of the gastrointestinal tract: a study of 117 cases presenting with gastrointestinal disease. Cancer 1978; 42: 693-707.
7. Herrmann R, Panahon AM, Barcos MP, Walsh D, Stutzman L. Gastrointestinal involvement in non-Hodgkin’s lymphoma. Cancer 1980; 46: 215-22.
8. d’Amore F, Christensen BE, Brincker H, et al. Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas. Danish LYFO Study Group. Eur J Cancer 1991; 27: 1201-8.
9. Krol AD, le Cessie S, Snijder S, et al. Primary extranodal non-Hodgkin’s lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol 2003; 14: 131-9.
10. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
11. Devesa SS, Fears T. Non-Hodgkin’s lymphoma time trends: United States and international data. Cancer Res 1992; 52: 5432s-40s.
12. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000; 92: 1240-51.
13. Chiu BC, Weisenburger DD. An update of the epidemiology of non-Hodgkin’s lymphoma. Clin Lymphoma 2003; 4: 161-8.
14. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107: 265-76.
15. Bertoni F, Zucca E. State-of-the-art therapeutics: marginal- zone lymphoma. J Clin Oncol 2005; 23: 6415-20.
16. Guidoboni M, Ferreri AJ, Ponzoni M, Doglioni C, Dolcetti R. Infectious agents in mucosa-associated lymphoid tissue-type lymphomas: pathogenic role and therapeutic perspectives. Clin Lymphoma Myeloma 2006; 6: 289-300.
17. Suarez F, Lortholary O, Hermine O, Lecuit M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 2006; 107: 3034-44.
18. Ferreri AJ, Dolcetti R, Du MQ, et al. Ocular adnexal MALT lymphoma: an intriguing model for antigendriven lymphomagenesis and microbial-targeted therapy. Ann Oncol 2007.
19. Haddadin WJ. Malignant lymphoma in Jordan: a retrospective analysis of 347 cases according to the World Health Organization classification. Ann Saudi Med 2005; 25: 398-403.
20. Sukpanichnant S. Analysis of 1983 cases of malignant lymphoma in Thailand according to the World Health Organization classification. Hum Pathol 2004; 35: 224-30.
21. Economopoulos T, Asprou N, Stathakis N, et al. Primary extranodal non-Hodgkin’s lymphoma in adults: clinicopathological and survival characteristics. Leuk Lymphoma 1996; 21: 131-6.
22. Chang KC, Huang GC, Jones D, et al. Distribution and prognosis of WHO lymphoma subtypes in Taiwan reveals a low incidence of germinal-center derived tumors. Leuk Lymphoma 2004; 45: 1375-84.
23. Isikdogan A, Ayyildiz O, Buyukcelik A, et al. Non-Hodgkin’s lymphoma in southeast Turkey: clinicopathologic features of 490 cases. Ann Hematol 2004; 83: 265-9.
24. Temmim L, Baker H, Amanguno H, Madda JP, Sinowatz F. Clinicopathological features of extranodal lymphomas: Kuwait experience. Oncology 2004; 67: 382-9.
25. Sutcliffe SB, Gospodarowicz MK. Localized extranodal lymphomas. In: Keating A, Armitage J, Burnett A, Newland A, eds. Hematological Oncology. Cam - bridge: Cambridge University Press, 1992: 189-222.
26. Gospodarowicz MK, Ferry JA, Cavalli F. Unique aspects of primary extranodal lymphomas. In: Mauch PM, Armitage JO, Harris NL, Dalla-Favera R, Coiffier B, eds. Non-Hodgkin’s Lymphomas. Philadelphia:Lippincott Williams & Wilkins, 2003: 685-707.
27. Shenkier TN, Connors JM. Primary extranodal non-Hodgkin’s lymphomas. In: Canellos GP, Lister TA, Young BD, eds. The Lymphomas, 2nd edn. Philadelphia: Saunders Elsevier, 2006: 325-47.
28. Dogan A, Du M, Koulis A, Briskin MJ, Isaacson PG. Expression of lymphocyte homing receptors and vascular addressins in low-grade gastric B-cell lymphomas of mucosa- associated lymphoid tissue. Am J Pathol 1997; 151: 1361-9.
29. Du MQ, Peng HZ, Dogan A, et al. Preferential dissemination of B-cell gastric mucosa-associated lymphoid tissue (MALT) lymphoma to the splenic marginal zone. Blood 1997; 90: 4071-7.
30. Drillenburg P, van der Voort R, Koopman G, et al. Preferential expression of the mucosal homing receptor integrin alpha 4 beta 7 in gastrointestinal non-Hodgkin’s lymphomas. Am J Pathol 1997; 150: 919-27.
31. Hancock B, Linch D, Delchier J, et al. Chlorambucil versus observation after anti-Helicobacter therapy in low-grade gastric lymphoma: results of the international LY03 trial (abstract). Ann Oncol 2005:16(supp 5); 56: abstract 074.
32. Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003; 101: 2489-95.
33. Cortelazzo S, Rossi A, Oldani E, et al. The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. Br J Haematol 2002; 118: 218-28.
34. Cortelazzo S, Rossi A, Roggero F, et al. Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large Bcell lymphoma. International Extranodal Lymphoma Study Group (IELSG). Ann Oncol 1999; 10: 1433-40.
35. Christie D, Gracia E, Gospodarowicz M, et al. Patterns of outcome and prognostic factors in primary bone lymphoma (osteolymphoma): a survey of 499 cases by the International Extranodal Lymphoma Study Group. Haematologica 2007; 92(Suppl 1): Abstract # 0717.
36. Ryan G, Martinelli G, Kuper-Hommel M, et al. Primary diffuse large B-cell lymphoma of the breast:prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 2008; 19: 233-41.
37. Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary largecell lymphoma of the testis in a survey by theInterna tional Extranodal Lymphoma Study Group. J Clin Oncol 2003; 21: 20-7.
38. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003; 21: 266-72.
39. Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. Blood 2000; 96: 410-19.
40. Pinotti G, Zucca E, Roggero E, et al. Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. Leuk Lymphoma 1997; 26: 527-37.
41. Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000; 95: 802-6.
42. Thieblemont C, Coiffier B. MALT lymphoma:sites of presentations, clinical features and staging procedures. In: Zucca E, Bertoni F, eds. MALT Lymphomas. Georgetown, TX: Landes Bioscience/Kluwer Academic, 2004: 60-80.